# This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

> **NCT01250951** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 111 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Thalassemia

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT01250951
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-07
- **Final completion:** 2011-09
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2016-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01250951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01250951, "This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01250951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*